Arrowhead shareholders have an opportunity to recover their investment losses.
Click "Join this Class Action" above.
Arrowhead Pharmaceuticals, Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. securities (NASDAQ: ARWR) from May 11, 2015 through November 8, 2016. The lawsuit seeks recovery of investor losses.
If you purchased shares of Arrowhead from May 11, 2015 through November 8, 2016, inclusive, and would like to join the action, please click "Join This Class Action" above.
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. - ARWR
New York, N.Y., November 16, 2016. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. securities (NASDAQ: ARWR) from May 11, 2015 through November 8, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Arrowhead investors under the federal securities laws.
To join the Arrowhead class action, go to http://www.rosenlegal.com/cases-997.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants made materially false and misleading statements and/or failed to disclose that: (1) ARC-520, one of Arrowhead’s drug candidates for patients with chronic hepatitis B infection, was fatal at certain doses; (2) consequently, the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; (3) Arrowhead had overstated the approval prospects and commercial viability of ARC-520; and (4) as a result, Arrowhead’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-997.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827